People who inherit one very rare gene mutation are virtually guaranteed to develop Alzheimer’s before they turn 50, but an American man has confused the forecasts, and confounded scientists.
“I’m 75-years-old, and I think I’m functioning fairly well,” said Doug Whitney. “I’m still not showing any of the symptoms of Alzheimer’s.”
Now a team of scientists is trying to understand how his brain has defied his genetic destiny, reports NPR.
“If we are able to learn what is causing the protection here, then we could translate that to therapeutic approaches and apply that to the more common forms of the disease,” said Dr Jorge Llibre-Guerra, an assistant professor of neurology at Washington University School of Medicine in St Louis.
One possibility is high levels of heat shock proteins found in Whitney’s brain, the team reports in the journal Nature Medicine.
There are hints that these proteins can prevent the spread of a toxic protein that is one of the hallmarks of Alzheimer’s, Llibre-Guerra said.
A genetic surprise
Early-onset Alzheimer’s is everywhere in Whitney’s family. His mother and 11 of her 13 siblings all had the disease by about 50. “None of them lasted past 60,” Whitney said.
The affected family members all carried a mutated version of a gene called presenilin 2. The variant causes a person’s brain to accumulate beta amyloid and phosphorylated tau proteins, the hallmarks of Alzheimer’s.
When Whitney turned 60 and still had no symptoms, he assumed he didn’t have the mutation. But he wanted to help others. So he volunteered for a study of families with early Alzheimer’s.
“I submitted my blood samples and to my great surprise, it came back positive for the Alzheimer’s gene,” Whitney said. “It was quite a shock.”
It was also a shock for scientists. Whitney was only the third person known to have escaped the effects of a presenilin mutation.
The first two came from a group in Colombia with mutations to the presenilin 1 gene. Whitney is the only person known to have resisted a mutation in the presenilin 2 gene, which is found on a different chromosome.
All three had lots of beta-amyloid in their brains. But surprisingly, they didn’t have much phosphorylated tau.
This form of tau is a misfolded protein that tends to appear in one brain area, then spread. But in Whitney’s brain, tau was confined to a small area involved in visual perception.
“One key element of the disease is having the tau protein spread through the brain,” Llibre-Guerra said. “That was not happening.”
The scientists set about trying to understand why.
They don’t have a definitive answer yet. But they are intrigued by the high levels of heat shock proteins in Whitney’s brain.
These proteins help protect brain cells from high temperatures and other forms of stress. They also seem to prevent healthy tau from misfolding into the toxic, phosphorylated form associated with Alzheimer’s.
“It may be the case that those proteins are preventing more tau to be misfolded, and then spread through the brain,” Llibre-Guerra suggested.
Protection from hot work?
Scientists told Whitney that the high levels of heat shock proteins in his brain might be the result of his life experience.
“I spent 20 years in the Navy, most of it in the hot spots, like the engine rooms of ships – 45 degrees is nothing on a ship,” he said.
That environment may have caused an increase in heat shock proteins, which were able to limit the spread of tau and prevent the onset of Alzheimer’s.
The scientists studying Whitney aren’t sure if that’s all, or even part, of the explanation. But they are hoping that the paper on Whitney will encourage other researchers to look for answers.
In the meantime, he plans to continue making his brain and body available to scientists. Later this year, he will return to Washington University where he has undergone repeated brain scans, blood draws, lumbar punctures, and even provided a sample of bone marrow.
His hope is that scientists will learn something that helps protect other brains from Alzheimer’s.
“I would love to see that happen,” he said, “while I’m still around.”
Study details
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Jorge J. Llibre-Guerra, M. Victoria Fernandez, Nelly Joseph-Mathurin et al.
Published in Nature Medicine on 10 February 2025
Abstract
We conducted an in-depth longitudinal study on an individual carrying the presenilin 2 p.Asn141Ile mutation, traditionally associated with dominantly inherited Alzheimer’s disease (AD), who has remarkably remained asymptomatic past the expected age of clinical onset. This study combines genetic, neuroimaging and biomarker analyses to explore the underpinnings of this resilience. Unlike typical progression in dominantly inherited AD, tau pathology in this case was confined to the occipital region without evidence of spread, potentially explaining the preservation of cognitive functions. Genetic analysis revealed several variants that, although not previously associated with protection against AD, suggest new avenues for understanding disease resistance. Notably, environmental factors such as significant heat exposure and a unique proteomic profile rich in heat shock proteins might indicate adaptive mechanisms contributing to the observed phenotype. This case underscores the complexity of Alzheimer’s pathology and suggests that blocking tau deposition could be a promising target for therapeutic intervention. The study highlights the need for further research to identify and validate the mechanisms that could inhibit or localise tau pathology as a strategy to mitigate or delay the onset of Alzheimer’s dementia.
NPR article – His genes forecast Alzheimer’s. His brain had other plans (Open access)
See more from MedicalBrief archives:
Patients who defied Alzheimer’s gene may help with therapies
New findings may mean hundreds of thousands misdiagnosed with Alzheimer’s
Australian scientists discover potential therapeutic target for Alzheimer’s